key: cord-0837024-jr6yie09 authors: Misra, Shubham; Nath, Manabesh; Hadda, Vijay; Vibha, Deepti title: Efficacy of various treatment modalities for nCOV‐2019: a systematic review and meta‐analysis date: 2020-08-18 journal: Eur J Clin Invest DOI: 10.1111/eci.13383 sha: 4fa68074a0df72197ca5cf534cee88d63a4dda4f doc_id: 837024 cord_uid: jr6yie09 BACKGROUND: Several therapeutic agents have been investigated for treatment of novel Coronavirus‐2019 (nCOV‐2019). We conducted a systematic review and meta‐analysis to assess the efficacy of various treatment modalities in nCOV‐2019 patients. METHODS: A literature search was conducted before 29 June 2020 in PubMed, Google Scholar, Cochrane library databases. A fixed‐effect model was applied if I(2) <50%, else results were combined using random‐effect model. Risk Ratio (RR) or Standardized Mean Difference (SMD) along‐with 95% Confidence Interval (95%CI) were used to pool the results. Between‐study heterogeneity was explored using influence and sensitivity analyses and publication bias was assessed using funnel plots. Entire statistical analysis was conducted in R version 3.6.2. RESULTS: Fifty studies involving 15 in‐vitro and 35 clinical studies including 9170 nCOV‐2019 patients were included. Lopinavir‐Ritonavir was significantly associated with shorter mean time to clinical recovery (SMD ‐0.32; 95%CI ‐0.57 to ‐0.06), Remdesivir was significantly associated with better overall clinical recovery (RR 1.17; 95%CI 1.07 to 1.29) and Tocilizumab was associated with less all‐cause mortality (RR 0.38; 95%CI 0.16 to 0.93). Hydroxychloroquine was associated with longer time to clinical recovery and less overall clinical recovery. It additionally had higher all‐cause mortality and more total adverse events. CONCLUSION: Our meta‐analysis suggests that except in vitro studies, no treatment has shown overall favorable outcomes in nCOV‐2019 patients. Lopinavir‐Ritonavir, Remdesivir and Tocilizumab may have some benefits while Hydroxychloroquine administration may cause harm in nCOV‐2019 patients. Results from upcoming large clinical trials may further clarify role of these drugs. Average half-maximal inhibitory concentration (IC 50 ), Average half maximal effective concentration (EC 50 ), Average cytotoxic concentration (CC 50 ) and Average selectivity Index (SI) of the various drugs included in the systematic review. (1) All-cause mortality; (2) total adverse events; (3) overall clinical recovery defined as the number of patients becoming negative for nCOV-2019 or significant improvement on chest CT and getting discharged from the hospital; (4) time to clinical recovery defined as the time taken in number of days for the negative conversion of nCOV-2019 or significant improvement on chest CT and getting discharged from the hospital. The criteria for the inclusion of studies in our systematic review and meta-analysis was: This article is protected by copyright. All rights reserved All titles and abstracts retrieved by searching available literature were screened independently by two authors (SM and MN) against the eligibility criteria. The information extracted from each eligible study included the first author, year of publication, study design, sample size, interventions (including type of treatment administered), outcome measures, main results. Any disagreement was resolved by mutual consensus among all the authors (DV, VH, SM, MN). The quality assessment was done for only the clinical studies included in our systematic review and meta-analysis by two independent authors (SM and MN) using the new Cochrane risk of bias tool for randomized controlled trials (ROB-2) for RCTs and Newcastle-Ottawa Scale (NOS) for non-RCTs, cohort and case-control studies. 14, 15 Any disagreement was resolved by consulting with the remaining authors of the review. The risk of publication bias was assessed by using Funnel plots and the asymmetry of the funnel plot was investigated using the Egger's regression test. 16 Dichotomous variables were represented by number (percentage) and the continuous variables were represented by mean and standard deviation (SD). If median, ranges and/or interquartile range were reported, then they were converted to mean and SD using the formula depending upon the sample size given by Wan et al. 2014 . 17 A meta-analysis was performed only for clinical studies and for those treatments in which required outcome data could be pooled from two or more studies. For dichotomous variables, the data was pooled using Risk ratio (RR) and 95% Confidence Interval (95% CI) while for continuous variables, the data was pooled using Standardized Mean Difference (SMD) and 95%CI. Heterogeneity among the included studies was investigated using Cochran's Q statistic, I 2 metric tests and by using prediction intervals. A fixed-effect model was applied if I 2 was less than 50%, else a random-effect model was used to pool the results. Labbé plots were used to determine the trend and between-study heterogeneity present in the binary outcome meta-analysis. The source of heterogeneity was further assessed by using the influence diagnostic tools and by This article is protected by copyright. All rights reserved conducting the sensitivity analyses and meta-regression analyses. All the statistical analysis was conducted using R version 3.6.2. Initial search yielded 1490 articles by searching various databases for published and preprint articles. After screening 928 articles, 377 full text articles were reviewed for eligibility and finally 50 studies were included in our systematic review and meta-analysis. Further, out of the 50 included studies, 15 were in vitro studies and 35 were clinical studies. The meta-analysis was finally conducted on 23 clinical studies. Fig. 1 represents the PRISMA flow diagram for the inclusion of studies in our systematic review and meta-analysis. The PRISMA checklist is available in the supplementary file 3. Overall, 15 in vitro published studies were included in the systematic review, which comprised majorly of treatments done on Vero E6 cells for viral titration, drug inhibition and cytotoxicity analyses. Nine studies were included from China, 5,18-25 three from United States of America (USA), [26] [27] [28] one each from Germany, 29 Netherlands 30 and Australia. 31 There were two studies 5,20 involving the anti-malarial drug on Hydroxychloroquine which had chloroquine as a positive control in both the studies. The studies had a wide range of multiplicity of infection (MOI) from 0.01 to 0.8 and an average half-maximal effective concentration (EC 50 ) of 6.84µM [0. 72 -12.96 ] in the treatment arm as compared to 6.415µM [5.47-7.36] in the control arm. The two studies showed potency in inhibiting nCOV-2019 in vitro in Vero cells. While the cytotoxic concentration (CC 50 ) of 249.50µM and selectivity index (SI) of 61.45 at an MOI of 0.01 in one study 20 were lower compared to the positive control, the EC 50 value of hydroxychloroquine was higher than chloroquine. These studies depicted that hydroxychloroquine had better efficacy and lesser cytotoxicity in inhibiting nCOV-2019 than Chloroquine in vitro but a higher dosage might be required for effectiveness, which could have adverse consequences. Two studies 23, 24 involving the broad-spectrum antiviral Remdesivir with MOI in the range of 0.02 to 0.05 exhibited average EC 50 of 11.96µM, CC 50 greater than 100µM and SI greater than This article is protected by copyright. All rights reserved 129.87. Remdesivir showed promising results in vitro and depicted potency inhibiting viral proliferation in Vero E6 cell line. Not only Remdesivir was able to block nCOV-2019 infection at lower concentrations it also had higher selectivity towards the viral cells that meant it had lower toxicity towards the host cells. One study each involving 47D11 H2L2 antibody, 30 Arbidol, 18 Auranofin, 28 Beta-d-N4hydroxycytidine, 26 Darunavir, 29 Antibodies n3086/n3113, 25 Interferon-α/ Interferon -β, 27 Ivermectin, 31 Lianhuaqingwen, 21 Chloroquine, 23 Lopinavir, 24 There was no significant difference in the mean age and sex distribution between any of the treatment and comparator groups included in our meta-analysis. Table-2 Eight studies 6, 10, 32, 33, [48] [49] [50] 59 consisting of 3400 nCOV-2019 cases were included in the metaanalysis and were divided into two groups: 1522 subjects to Hydroxychloroquine group and 1878 subjects to control group. Compared to the control group, Hydroxychloroquine had an increased risk of having total adverse events (RR 1.82; 95% CI 1.57 to 2.12) and was associated with a longer time to clinical recovery (SMD 0.55; 95% CI 0.21 to 0.89). However, Hydroxychloroquine was not found to be significantly associated with all-cause mortality (RR 1.22; 95%CI 0.76 to 1.95) and overall clinical recovery (RR 0.93; 95%CI 0.84 to 1.04) ( Fig. 2(a-d) ). Although, through the Labbé plots, we did observe a trend that all-cause mortality was more towards the Hydroxychloroquine group (supplementary file 2) while overall clinical recovery was more in the control group ( Fig. 8(a) ). Four studies [36] [37] [38] [39] consisting of 397 nCOV-2019 cases were included in the meta-analysis and were divided into two groups: 227 subjects to Lopinavir-Ritonavir group and 170 subjects control group. There was no significant association between the two groups in terms of total adverse events (RR 1.73; 95%CI 0.57 to 5.26) and overall clinical recovery (RR 1.08; 95%CI 0.94 to 1.24). Labbé plot observed a trend of having more adverse events towards the Lopinavir-Ritonavir group (supplementary file 2). A borderline association was observed depicting a trend in terms of a shorter mean time (in days) to clinical recovery in the Lopinavir-Ritonavir group compared to the control group (SMD -0.47; 95%CI -1.00 to 0.07) ( Fig. 3 (a-c) ). Due to less number of available studies, a meta-analysis could not be performed for assessing the all-cause mortality between the two groups. This article is protected by copyright. All rights reserved The benefit/harm of Lopinavir-Ritonavir treatment over Arbidol treatment was assessed in two studies 38 Two studies 38, 39 consisting of 134 nCOV-2019 cases were included in the meta-analysis and were divided into two groups: 69 subjects to Arbidol group and 65 subjects to control group. When compared to the control group, treatment with Arbidol was not found to be associated with incidence of the total adverse events (RR 1.80; 95%CI 0.52 to 6.19) or overall clinical recovery (RR 1.08; 95%CI 0.85 to 1.38) ( Fig. 4 (a, b) ). The findings were concurrent when analysed using the Labbé plots (supplementary file 2). A meta-analysis could not be performed for the remaining outcome measures of all-cause mortality and time to clinical recovery due to fewer number of studies. The effect of Remdesivir treatment over placebo was assessed in two RCTs 11 This article is protected by copyright. All rights reserved compared to placebo group ( Fig. 5 (a-d) ). Similar findings were observed in Labbé plot analysis as well (supplementary file 2). Five studies [42] [43] [44] [45] 62 consisting of 674 nCOV-2019 cases were included in the meta-analysis and were divided into two groups: 515 subjects to Corticosteroid group and 159 subjects to control group. Administration of Corticosteroid treatment was found to have no significant association with all-cause mortality (RR. 1.17; 95%CI 0.37 to 3.65) or the average time to clinical recovery (SMD 0.16; 95%CI -0.26 to 0.58) compared to the control group ( Fig. 6 (a, b) ). Since enough studies could not be pooled, no meta-analysis was performed to assess the effect of Corticosteroid treatment on the total adverse events and overall clinical recovery. Four studies [55] [56] [57] [58] consisting of 806 nCOV-2019 cases were included in the meta-analysis and were classified into two groups: 294 subjects to Tocilizumab and 512 subjects in control groups. Tocilizumab was found to have significantly less all-cause mortality compared to the control group (RR 0.38; 95%CI 0.16 to 0.93). However, there was no significant difference between the two groups in terms of overall clinical recovery (RR 1.11; 95%CI 0.80 to 1.54). Due to less number of studies, a meta-analysis was not possible for the other two outcomes of interest. The combination of Hydroxychloroquine and Azithromycin was tested in three studies 6, 49, 50 including 1253 nCOV-2019 cases wherein, 854 cases were allocated to the Hydroxychloroquine + Azithromycin treatment group and the rest 399 cases to the control group. The combination of Hydroxychloroquine + Azithromycin was significantly associated with a higher risk of all-cause mortality compared to the control group (RR 2.01; 95%CI 1.47 to 2.73) while no association was observed between the two in terms of overall clinical recovery (RR 0.94; 95%CI 0.72 to 1.23) ( Fig. 7 (a, b) ). However, we did observe a slight trend in a lesser overall clinical recovery towards the Hydroxychloroquine + Azithromycin This article is protected by copyright. All rights reserved treatment group using the Labbé plot (supplementary file 2). The total adverse events and time to clinical recovery outcomes could not be assessed due to limited number of studies. The publication bias was assessed using funnel plot analysis for all those treatment modalities wherein data from more than two studies could be pooled together. The shape of the funnel plots did not show any evidence of significant publication bias except for two instances wherein Hydroxychloroquine was compared with control group to assess the overall clinical recovery outcome (P-value: 0.003) and Lopinavir-Ritonavir treatment was compared with control group to assess the total adverse event outcome (P-value: 0.02). This was confirmed by the significant p-values obtained from the Egger's regression test. The pvalue of Egger's regression test was not significant for the presence of any publication bias for the rest of the funnel plots. Fig. 8 (b) represents the funnel plot analysis carried out for hydroxychloroquine vs. control group for assessing the overall clinical recovery outcome. The remaining funnel plots have been depicted in the Table S2 .1 of supplementary file 2. A meta-regression analysis was conducted to determine if the risk of bias and ethnicity of each study were associated with the overall effect size difference. A meta-regression analysis was performed only for those treatments where data from more than two studies was pooled. The two predictor variables used in the meta-regression analysis were categorized as: risk of bias (low, some concerns, high); and ethnicity (Asian, Caucasian). The "ethnicity" variable as a predictor, was found to be significantly associated with the overall effect size difference while assessing the time to clinical recovery outcome between Hydroxychloroquine and control group (P-value: 0.02) and assessing the all-cause mortality outcome between Hydroxychloroquine and control group (P-value<0.001) (( Fig. 8(c) ) and similar outcome between Corticosteroid and control group (P-value: 0.007). The "risk of bias" variable as a predictor was also found to be significantly associated with the overall effect size difference while assessing the all-cause mortality outcome between Corticosteroid and control group (P-value: 0.009) and while assessing the time to clinical recovery outcome between Hydroxychloroquine and control group (P-value: 0.02). Risk of bias and ethnicity This article is protected by copyright. All rights reserved did not have any association with the overall effect size difference for assessing the remaining outcomes between other treatment groups. The risk of bias was assessed using ROB-2 tool for RCTs and NOS for non-RCTs, cohort and case-control studies. For NOS, the total score was divided into three categories: (1) 1-3 (High risk of bias); (2) 4-6 (Some concerns); 7-9 (Low risk of bias). Overall, 9 (25.71%) studies included in our review had an overall low risk of bias, 22 (62.86%) studies had some concerns related to the risk of bias while four studies (11.43%) had high risk of bias. All the four studies 10,32,34,61 with a high risk of bias belonged to the RCT sub-group ( Fig. 9 (a, b) ). The individual items for the quality scale are depicted in supplementary file 1. Influence diagnostics tools and sensitivity analysis were used to further explain the heterogeneity observed in our results and to identify the outlier studies which could be significantly affecting the overall pooled effect estimates. The influence diagnostics and sensitivity analysis were performed for treatments in which data from more than two studies was pooled. The influence diagnostic tools generated two plots including 1) Baujat plots; 2) Influence analysis plots; and two plots for sensitivity analysis including 3) leaveone-out analysis ordered by heterogeneity and 4) leave-one-out analysis ordered by effect size. The Baujat and influence analysis plots identified one potential outlier namely, Yu B, 2020 33 while assessing the all-cause mortality outcome in Hydroxychloroquine vs. control group analysis. After conducting the sensitivity analysis by omitting a single study in each turn (ordered by both effect size and I 2 ), the overall effect size and amount of heterogeneity changed significantly by omitting the Yu B, 2020 study. Hydroxychloroquine was found to be significantly associated with the risk of having more all-cause mortality compared to control group (RR 1.57; 95%CI 1.30 to 1.90; I 2 = 0%) (Fig. 10) . A borderline association was observed between Hydroxychloroquine and less overall clinical recovery when Gautret P, 2020 6 outlier study was omitted in the sensitivity analysis (RR 0.92; 95%CI 0.84 to 1.00; I 2 = 67%). This article is protected by copyright. All rights reserved The influence diagnostic tools identified Ye XT, 2020 37 study as a potential outlier while assessing the time to clinical recovery outcome between Lopinavir-Ritonavir and control groups; and after omitting this study in the sensitivity analysis we observed that Lopinavir-Ritonavir was significantly associated with a shorter mean time to clinical recovery than the control group (SMD -0.32; 95%CI -0.57 to -0.06, I 2 = 0%). While assessing the all-cause mortality outcome between Corticosteroid and control groups, we observed Lu X, 2020 44 as a potential outlier study. After removing the outlier, a significant association was observed between less all-cause mortality and Corticosteroid treatment with reduced heterogeneity (RR 0.61; 95%CI 0.37 to 0.98, I 2 = 0%). The significant association between less all-cause mortality and Tocilizumab treatment was lost when Capra R, 2020, 58 Guaraldi G, 2020 55 and Campochiaro C, 2020 56 were omitted sequentially in the sensitivity analysis. Our This article is protected by copyright. All rights reserved of harm, our meta-analysis suggests that Hydroxychloroquine treatment compared to control group and Lopinavir-Ritonavir treatment compared to Arbidol treatment were significantly associated with more total adverse events in nCOV-2019 patients. Hydroxychloroquine was also associated with a longer time to clinical recovery compared to control group. Hydroxychloroquine combined with Azithromycin was associated with higher all-cause mortality compared to control group. We did not observe any significant association in terms of either benefit or harm for the remaining treatments administered to nCOV-2019 patients when analysed against their respective comparator groups. Although This article is protected by copyright. All rights reserved RCTs were reported, Hydroxychloroquine no longer had any benefit over standard care and instead was associated with more adverse events and higher mortality rate. 10, 32 We also conducted a subgroup analysis based on study design which further strengthened this notion. Hydroxychloroquine compared to control group was found to be associated with a longer time to clinical recovery in both non-RCTs/cohort study subgroup as well as in the RCT subgroup (Fig S2.2 in supplementary file 2) . Two recent meta-analyses conducted by Ren L et al. 2020 and Wang J et al. 2020 found that patients taking Chloroquine or Hydroxychloroquine had more adverse events compared to patients assigned to placebo group. 65, 66 Another meta-analysis published a couple of months ago by Sarma et al. 2020 found no association of Hydroxychloroquine with virological cure, death or clinical worsening and safety in nCOV-2019 patients. 67 Similar findings on Hydroxychloroquine with or without azithromycin were observed from another meta-analysis of five trials which although did observe a trend but the results were not found to be statistically significant in also observed a delayed time to virus clearance in the corticosteroid group compared to controls (MD 3.78; 95%CI 1.16 to 6.41). 71 The findings of our meta-analysis are also in line with the previously published meta-analyses on corticosteroids. We did not observe any significant association between corticosteroid treatment and all-cause mortality and time to clinical recovery, but after conducting the sensitivity analysis, we observed a significant association between less all-cause mortality and Corticosteroid treatment after removing the outlier study. However, the result stems from a pooled synthesis of only a couple of trials and further large RCTs are required to confirm/refute our findings. This article is protected by copyright. All rights reserved Use of Convalescent Plasma has been shown to be extremely promising in some recently published case-series. 73, 74 Only one RCT was available on determining the effectiveness of Convalescent plasma compared to controls, 47 thus we could not conduct a meta-analysis. However, we systematically reviewed the trial and observed that convalescent plasma was neither associated with more/less adverse events nor with more/less overall clinical recovery compared to control group (supplementary file 2). Although, we observed a trend of more overall clinical recovery towards the Convalescent plasma arm (RR 1.20; 95% CI 0.80 to 1.81). A recently published systematic review of five studies by Rajendran K et al. 2020 concluded that plasma therapy in nCOV-2019 patients was safe, clinically effective and was associated with a reduced mortality. 75 Results from ongoing clinical trials on plasma therapy are awaited and will give us a better insight into the effectiveness of Convalescent Plasma in treating nCOV-2019 patients. Although we made sure that our systematic review and meta-analysis was conducted very comprehensively, certain inherent and obvious limitations cannot be ignored. Firstly, due to the limited number of studies, our meta-analysis pooled the data from RCTs and non-RCTs/cohort/case-control studies together which is generally not advisable. However, we did conduct a subgroup analysis based on study design wherever possible to separate the RCTs from non-RCTs/cohort/case-control studies. Secondly, all outcome measures could not be assessed for all the potential treatments due to scarcity of literature. Lastly, since several clinical trials on nCOV-2019 treatments are currently ongoing, the results of our metaanalysis might change significantly owing to the findings published in near future. Nonetheless, our meta-analysis presents preliminary evidence of benefit/harm of the possible treatments being administered to nCOV-2019 patients and these preliminary results could be used for conducting and planning large clinical trials and prospective multicentric cohort studies. The result of this systematic review and meta-analysis suggest that Hydroxychloroquine and Remdesivir have shown promising results in the in vitro studies. However, based on the This article is protected by copyright. All rights reserved current clinical evidence, our meta-analysis did not observe significant beneficial effect of any treatment on nCOV-2019 patients apart from a significant association in better overall clinical recovery of Remdesivir compared to placebo, less all-cause mortality in Tocilizumab arm compared to controls and a borderline association in time to clinical recovery of Lopinavir-Ritonavir treatment compared to control group. Hydroxychloroquine with or without azithromycin might be associated with higher all-cause mortality, more total adverse events, less overall clinical recovery and a longer mean time to clinical recovery. Results from further large clinical trials are warranted. Accepted Article Wang This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved A Novel Coronavirus from Patients with Pneumonia in China An interactive web-based dashboard to track COVID-19 in real time SARS and MERS: recent insights into emerging coronaviruses Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19 | NIH: National Institute of Allergy and Infectious Diseases EUA Hydroxychloroquine sulfate Health Care Provider Fact Sheet 04272020 Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment 19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment Accepted Article This article is protected by copyright. All rights reserved 10 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement RoB 2: a revised tool for assessing risk of bias in randomised trials Bias in meta-analysis detected by a simple, graphical test Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro Accepted Article This article is protected by copyright. All rights reserved In vitro inhibition of coronavirus replications by the traditionally used medicinal herbal extracts, Cimicifuga rhizoma, Meliae cortex, Coptidis rhizoma, and Phellodendron cortex Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Lianhuaqingwen exerts anti-viral and antiinflammatory activity against novel coronavirus (SARS-CoV-2) Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro Identification of Human Single-Domain Antibodies against SARS-CoV-2 An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Antiviral activities of type I interferons to SARS-CoV-2 infection The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells Accepted Article This article is protected by copyright. All rights reserved Lack of antiviral activity of darunavir against SARS-CoV A human monoclonal antibody blocking SARS-CoV-2 infection The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19 Treating COVID-19 with Chloroquine Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019 Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Adjuvant corticosteroid therapy for critically ill patients with COVID-19 Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumonia Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19 Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Accepted Article This article is protected by copyright. All rights reserved Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19 Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State Early Short Course Corticosteroids in Hospitalized Patients with COVID-19 Remdesivir for the Treatment of Covid-19 -Preliminary Report Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact Tocilizumab in patients with severe COVID-19: a retrospective cohort study Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results From SMAtteo COvid19 REgistry (SMACORE) Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia Accepted Article This article is protected by copyright. All rights reserved Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial Impact of glucocorticoid treatment in SARS-CoV-2 infection mortality: a retrospective controlled cohort study Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review Assessment of Hydroxychloroquine and Chloroquine Safety Profiles: A Systematic Review and Meta-Analysis. medRxiv [Internet] 2020 Benefits and Risks of Chloroquine and Hydroxychloroquine in The Treatment of Viral Diseases: A Meta-Analysis of Placebo Randomized Controlled Trials. Accepted Article This article is protected by copyright. All rights reserved medRxiv Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis Systematic Review and Meta-analysis of the Effectiveness and Safety of Hydroxychloroquine The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A metaanalysis. medRxiv [Internet] 2020 Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis Effectiveness and Safety of Glucocorticoids to Treat COVID-19: A Rapid Review and Meta-Analysis. medRxiv [Internet] 2020 Treatment of 5 Critically Ill Patients With COVID-19 With